Calcitonin receptors of human osteoclastoma

G. C. Nicholson, M. A. Horton, P. M. Sexton, C. S. D'Santos, J. M. Moseley, B. E. Kemp, J. A.S. Pringle, T. J. Martin

Research output: Contribution to journalArticleResearchpeer-review

62 Citations (Scopus)


Osteoclast-rich cultures were prepared by disaggregation of osteoclastomas (giant cell tumour of bone) and settlement onto glass or plastic surfaces. Autoradiography using [ 125 I]-salmon calcitonin ([ 125 I]-sCT) revealed specific binding only to multinucleate giant cells (osteoclasts) and a minor population of mononuclear cells. [ 125 I]-sCT competitive binding studies indicated a K(d) of 5 x 10 -10 M and receptor number of approximately 1 million sites/osteoclast. sCT treatment resulted in a dose-dependent rise in cAMP (EC 50 10 -10 M). Homogenates of an osteoclastoma also demonstrated specific binding of [ 125 I]-sCT. Chemical cross-linking of a labelled synthetic sCT derivative, [ 125 I]-[Arg 11,18 , Lys 14 ]-sCT, using disuccinimidyl suberate, resulted in labelling of a receptor component of approximate M(r) 85-90,000. The multinucleate giant cells (osteoclasts) of human osteoclastomas possess large number of CT receptors which exhibit the same binding kinetics and apparent M(r) as those of other CT target cells.

Original languageEnglish
Pages (from-to)585-589
Number of pages5
JournalHormone and Metabolic Research
Issue number11
Publication statusPublished - 1 Jan 1987
Externally publishedYes

Cite this

Nicholson, G. C., Horton, M. A., Sexton, P. M., D'Santos, C. S., Moseley, J. M., Kemp, B. E., Pringle, J. A. S., & Martin, T. J. (1987). Calcitonin receptors of human osteoclastoma. Hormone and Metabolic Research, 19(11), 585-589.